Primary and secondary prevention of stroke by antihypertensive drug treatment

Expert Review of Neurotherapeutics

Volumn 4, Issue 6, 2004, Pages 1023-1031

  Wang, Ji Guang ^a   Li, Yan ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Blood pressure; Clinical trial; Meta analysis; Prevention; Stroke

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; INDAPAMIDE; ISRADIPINE; LACIDIPINE; LOSARTAN; NIFEDIPINE; NISOLDIPINE; PERINDOPRIL; RAMIPRIL; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; PRIMARY PREVENTION; REGRESSION ANALYSIS; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; HUMANS; HYPERTENSION; META-ANALYSIS; ODDS RATIO; REGRESSION ANALYSIS; RISK;

EID: 8344277925     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.6.1023     Document Type: Review

References (71)

1. He J, Klag MJ, Wu Z, Whelton PK. Stroke in the People's Republic of China. II. Meta-analysis of hypertension and risk of stroke. Stroke 26, 2228-2232 (1995).
2. Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N. Engl. J. Med. 333, 1392-1400 (1995).
3. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002). Describes the largest ever meta-analysis of observational studies on the relationship between mortality and blood pressure, and clearly shows that blood pressure is positively associated with mortality in all age groups.
4. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 349, 1269-1276 (1997).
5. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335, 827-838 (1990).
6. Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355, 865-872 (2000).
7. Liu L, Wang JG, Gong L et al. Comparison of active treatment and placebo in older patients with isolated systolic hypertension. J. Hypertens. 16, 1823-1829 (1998).
8. Wang JG, Staessen JA, Gong L, Liu L, for the Systolic Hypertension in China (Syst-China) Collaborative Group. Chinese trial on isolated systolic hypertension in the elderly. Arch. Intern. Med. 160, 211-220 (2000).
9. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in six European countries, Canada, and the United States. JAMA 289, 2363-2369 (2003).
10. Rothwell PM, Coull AJ, Giles MF et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363, 1925-1933 (2004). Shows that stroke incidence has decreased over the last 20 years, mainly due to the use of blood pressure-lowering agents and other preventive treatments.
11. Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS). A randomized controlled trial. JAMA 276, 785-791 (1996).
12. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353, 611-616 (1999).
13. National Intervention Co-operative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 34, 1129-1133 (1999).
14. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354, 1751-1756 (1999).
15. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 356, 366-372 (2000).
16. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calciumantagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356, 359-365 (2000).
17. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283, 1967-1975 (2000).
18. Zanchetti A, Agabiti Rosei E, Dal Palú C et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. 16, 1667-1676 (1998).
19. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 39. Br. Med. J. 317, 713-720 (2000).
20. Black HR, Elliott WJ, Grambsch P et al. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular End points (CONVINCE) Trial. JAMA 289, 2073-2082 (2003).
21. Dahlöf B, Devereux B. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
22. Zanchetti A, Bond G, Hennig M et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106, 2422-2427 (2002).
23. The ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-convertuig enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
24. Wing LMH, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348, 583-592 (2003).
25. Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J. Hypertens. 21, 875-886 (2003).
26. Frohlich ED. Treating hypertension. What are we to believe? N. Engl. J. Med. 348, 639-641 (2003).
27. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. (Correction published Lancet 359, 360 [2002]). Lanicet 358, 1305-1315 (2001).
28. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. (Correction published Lancet 359, 360 [2002]). Lanicet 358, 1305-1315 (2001).
29. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 21, 1055-1076 (2003).
30. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br. Med. Bull. 50, 272-298 (1994).
31. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004-1010 (2002).
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. Br. Med. J. 317, 703-713 (1998).
33. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. Am. J. Med. 69, 725-732 (1980).
34. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischemic attack. Lancet 358, 1033-1041 (2001).
35. Carter AB. Hypotensive therapy in stroke survivors. Lancet 1, 485-489 (1970).
36. Hypertension-Stroke Co-operative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 229, 409-418 (1974).
37. PATS Collaborative Group. Poststroke antihypertensive treatment study. A preliminary result. Chin. Med. J. 108, 710-717 (1995).
38. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient isachemic attack or nondisabling stroke. Stroke 24, 543-548 (1993).
39. Eriksson S, Olofsson BO, Wester PO, for the TEST Study Group. Atenolol in the secondary prevention of stroke. Cerebrovasc. Dis. 5, 21-25 (1995).
40. Amery A, Birkenhäger W, Brixko P et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1349-1354 (1985).
41. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br. Med. J. 293, 1145-1151 (1986).
42. Dahlöf B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338, 1281-1285 (1991).
43. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br. Med. J. 304, 405-412 (1992).
44. Medical Research Council Working Party. Medical Research Council trial of treatment of mild hypertension: principal results. Br. Med. J. 291, 97-104 (1985).
45. SHEP Co-operative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265, 3255-3264 (1991).
46. Gong L, Zhang W, Zhu Y et al. Shanghai trial of nifedipine in the elderly (STONE). J. Hypertens. 14, 1237-1245 (1996).
47. Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276, 1886-1892 (1996).
48. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. (Correction published Lancet 350, N1636 [1997]). Lancet 350, 757-764 (1997).
49. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. (Correction published Lancet 350, N1636 [1997]). Lancet 350, 757-764 (1997).
50. Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet 1, 1261-1267 (1980).
51. US Public Health Service Hospitals Cooperative Study Group (McFate Smith WM). Treatment of mild hypertension: results of a 10-year intervention trial. Circ. Res. 40, I-98-I-105 (1977).
52. Veterans Administration Co-operative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115-129 mmHg. JAMA 202, 116-122 (1967).
53. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 340, 677-684 (1999).
54. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351, 1755-1762 (1998).
55. MacMahon S, Sharpe N, Gamble G et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J. Am. Coll. Cardiol. 36, 438-443 (2000).
56. Teo KK, Burton JR, Buller CE et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 102, 1748-1754 (2000).
57. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
58. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000).
59. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
60. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
61. Parving HH, Lehnert H, Bröchner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001).
62. Wang JG, Staessen JA. Conventional therapy and newer drug classes for cardiovascular protection in hypertension. J. Am. Soc. Nephrol. 13(Suppl. 3), S208-S215 (2002).
63. Staessen JA, Wang JG, Birkenhäger WH. Outcome beyond blood pressure control? Eur. Heart J. 24, 504-514 (2003).
64. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
65. 1-receptor mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil. J. Renin Angiotensin Aldosterone Syst. 2, 103-106 (2001).
66. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004). Shows that amlodipine-based antihypertensive regimen controls blood pressure better and is more effective in cardiovascular prevention than varlsartan as the first-line drug.
67. Schrier RW, Estacio RO, Esler A, Menler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 61, 1086-1097 (2002).
68. Marre M, Lièvre M, Vasmant D et al. Determinants of elevated urinary albumin in the 4,937 Type 2 diabetic subjects recruited for the DIABHYCAR study in Western Europe and Northern Africa. Diabet. Care 23(Suppl. 2), B40-B48 (2000).
69. Dens JA, Desmet WJ, Coussement P et al. Usefulness of nisoldipine for prevention of restenosis after percutaneous transluminal coronary angioplasty (results of the NICOLE study). NIsoldipine in COronary artery disease in LEuven. Am. J. Cardiol. 87, 28-33 (2001).
70. Byington RB, Miller ME, Herrington D et al. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). Am. J. Cardiol. 80, 1087-1090 (1997).
71. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102, 1503-1510 (2000).